Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20772602 | 0.93 | CHRNB2 (0.40) | CHRNB4CHRNA3CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7525265 | 0.81 | KDM1A (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL7413475 | 0.80 | CHRNB2 (0.58) | CHRNB4CHRNA3CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL16461977 | 0.80 | KDM1A (0.42) | PARP15PARP10PARP2 | |
| SCHEMBL7824499 | 0.80 | CHRNB2 (0.58) | CHRNB4CHRNA3CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7827076 | 0.80 | CHRNA3 (0.61) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL7825495 | 0.80 | CHRNA3 (0.61) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7826412 | 0.79 | CHRNB2 (0.57) | CHRNB4CHRNA3CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7827114 | 0.79 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7825587 | 0.79 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3676248-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-07-08 | — | — | EP | disclosed |
| CN-111132961-A | Bisaryloxy derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| WO-2019045035-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | CHRNB4 171/4885CHRNA3 127/4885CHRNA7 159/4885 |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN3A, SCN2B | CHRNB4 171/4885CHRNA3 127/4885CHRNA7 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.